Bolt Biotherapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Bolt Biotherapeutics, Inc. (BOLT) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $513.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-12
- Bolt Biotherapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $513.00K, a 64.35% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $1.44M, a 21.28% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $1.83M.
- Bolt Biotherapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was -$269.00K, a 117.11% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | $513.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $1.44M 10-K · filed 2026-03-12 |
| 2023-12-31 | $1.83M 10-K · filed 2025-03-24 |
| 2022-12-31 | -$269.00K 10-K · filed 2024-03-21 |
| 2021-12-31 | $1.57M 10-K · filed 2023-03-29 |
| 2020-12-31 | $918.00K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |